US FDA advisers to discuss Pfizer’s maternal RSV vaccine
By Raghav Mahobe and Mariam Sunny (Reuters) – Advisers to the U.S. Food and Drug Administration on Thursday will discuss Pfizer Inc’s experimental respiratory syncytial virus (RSV) vaccine intended to protect infants through six months of age when given to expectant mothers. A positive vote by the panel on the vaccine’s effectiveness and safety would boost its chances of becoming the first available maternal shot to protect babies, who are […]